adenine has been researched along with Cancer of Prostate in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days." | 2.67 | Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study. ( Ahmann, F; Blumenstein, B; Craig, JB; Crawford, ED; Eisenberger, M; Marshall, ME; Thompson, IM, 1994) |
| "AR is also a critical mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the natural history of the disease." | 2.41 | Molecular biology of the androgen receptor. ( Gelmann, EP, 2002) |
| " Therefore, we investigated the characteristics of autophagic response to ARN-509 treatment and evaluated the potential effect of a combination with autophagy inhibition." | 1.56 | Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells. ( Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020) |
| "Upon metabolic perturbation, prostate cancer cell lines upregulate MTAP and this correlates with recovery of SAM levels." | 1.43 | The essential role of methylthioadenosine phosphorylase in prostate cancer. ( Affronti, HC; Bistulfi, G; Foster, BA; Gillard, B; Karasik, E; Mohler, J; Morrison, C; Phillips, JG; Smiraglia, DJ, 2016) |
| " Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells." | 1.42 | Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. ( Anoopkumar-Dukie, S; Bernaitis, N; Chess-Williams, R; Christie, D; Davey, AK; Forbes, A; McDermott, CM; McFarland, AJ; Perkins, AV; Pickard, RD; Spencer, BH, 2015) |
| "Using established prostate cancer cell lines and novel conditionally reprogrammed cells (CRCs) derived from prostate cancer patients; we have defined the mechanisms of VMY-induced prostate cancer cell death." | 1.40 | The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. ( Abdelgawad, I; Albanese, C; Avantaggiati, ML; Choudhry, MU; Dritschilo, A; Feldman, AS; Heckler, M; Kallakury, B; Lee, RJ; Liu, X; Lynch, J; Naeem, A; Parasido, E; Pestell, RG; Ringer, L; Rodriguez, O; Schlegel, R; Sirajuddin, P; Sivakumar, A; Tricoli, L; Waye, S; Wu, CL; Yenugonda, V, 2014) |
| "We report that in breast and prostate cancer cells that contain leukocyte levels of p110δ, p110δ activity dampens the activity of the PTEN tumor suppressor." | 1.38 | High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. ( Andreou, M; Makrigiannakis, A; Papakonstanti, EA; Stratigi, K; Tzenaki, N; Vanhaesebroeck, B; Vergetaki, A, 2012) |
| "The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases." | 1.38 | Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. ( Ehrlich, M; Pinkas-Kramarski, R; Schmukler, E; Shai, B, 2012) |
| "TNF-alpha levels in prostate cancer correlate with the extent of disease and are significantly elevated in the metastatic stage." | 1.38 | Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis. ( D'Alessio, A; Facchiano, A; Filippini, A; Giampietri, C; Marini, ES; Padula, F; Petrungaro, S; Ziparo, E, 2012) |
| "Studies using the PC-3 human prostate cancer cell line demonstrate that X-ray excitation of these psoralen-functionalized Y(2)O(3) nanoscintillators yields concentration-dependent reductions in cell number when compared to control cultures containing psoralen-free Y(2)O(3) nanoscintillators." | 1.37 | Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation. ( Gregas, MK; Lauly, B; Scaffidi, JP; Vo-Dinh, T; Zhang, Y, 2011) |
| "In summary, the establishment of XMRV infection in patients may be dependent on infection of A3G/A3F-deficient cells, and cells expressing low levels of A3G/A3F, such as prostate cancer cells, may be ideal producers of infectious XMRV." | 1.36 | Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. ( Burdick, R; Chaipan, C; Delviks-Frankenberry, KA; Hu, WS; Paprotka, T; Pathak, VK; Venkatachari, NJ, 2010) |
| "Gossypol has been reported to have a potent anticancer activity in many types of cancer." | 1.36 | Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. ( An, QX; Chen, R; Hu, XB; Huang, XF; Mu, SJ; Wu, DC; Xia, AJ; Yang, SM; Yi, J; Zhan, YH; Zhang, XQ, 2010) |
| "The androgen-dependent prostate cancer cell line, LNCaP, expresses the EGFR as well as two additional members of the family; ErbB-2 and ErbB-3, which can be activated by neuregulin (NRG) isoforms." | 1.32 | Neuregulin promotes autophagic cell death of prostate cancer cells. ( Di-Segni, A; Lupowitz, Z; Pinkas-Kramarski, R; Tal-Or, P, 2003) |
| "Nuclear extracts from PC-3 and DU-145 prostate cancer cell lines are defective in the incision of 8-oxoG, 5OHC and thymine glycol (TG) relative to the non-malignant prostate cell line." | 1.32 | Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. ( Dizdaroglu, M; Evans, MK; Jaruga, P; Lohani, A; Nyaga, SG; Trzeciak, AR, 2004) |
| "Fludarabine phosphate was then given intraperitoneally for 5 days at 75 mg/m2/day." | 1.32 | Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. ( Both, GW; Cameron, F; Cooke-Yarborough, C; Coulston, N; Ho, T; Lockett, TJ; Martiniello-Wilks, R; Moghaddam, M; Molloy, PL; Russell, PJ; Shaw, JM; Smith, IK; Wang, XY; Webster, LK, 2004) |
| " Data from correlation analysis of the log ratios for normal tissues from cancer were consistent with an age-dependent, dose-response relationship." | 1.31 | Age-related radical-induced DNA damage is linked to prostate cancer. ( Barker, EA; Johnson, PM; Malins, DC; Polissar, NL; Vinson, MA; Wheeler, TM, 2001) |
| "Human prostate cancer cells (LNCaP) were grown under different conditions and analyzed for differential expression of mRNA." | 1.29 | Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells. ( Kirschenbaum, A; Levine, AC; Liu, BC; Miniati, DN; Robbins, SE; Shu, WP, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.56) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 6 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gakis, G | 1 |
| Perner, S | 1 |
| Stenzl, A | 1 |
| Renninger, M | 1 |
| Panda, PK | 1 |
| Patra, S | 1 |
| Naik, PP | 1 |
| Praharaj, PP | 1 |
| Mukhopadhyay, S | 1 |
| Meher, BR | 1 |
| Gupta, PK | 1 |
| Verma, RS | 1 |
| Maiti, TK | 1 |
| Bhutia, SK | 1 |
| Affronti, HC | 2 |
| Rowsam, AM | 1 |
| Pellerite, AJ | 1 |
| Rosario, SR | 1 |
| Long, MD | 1 |
| Jacobi, JJ | 1 |
| Bianchi-Smiraglia, A | 1 |
| Boerlin, CS | 1 |
| Gillard, BM | 1 |
| Karasik, E | 2 |
| Foster, BA | 2 |
| Moser, M | 1 |
| Wilton, JH | 1 |
| Attwood, K | 1 |
| Nikiforov, MA | 1 |
| Azabdaftari, G | 1 |
| Pili, R | 1 |
| Phillips, JG | 2 |
| Casero, RA | 1 |
| Smiraglia, DJ | 2 |
| Eberli, D | 1 |
| Kranzbühler, B | 1 |
| Mortezavi, A | 1 |
| Sulser, T | 1 |
| Salemi, S | 1 |
| Walters, C | 1 |
| Reed, M | 1 |
| Bartholomew, S | 1 |
| Bommareddy, A | 1 |
| Voss, G | 1 |
| Edsjö, A | 1 |
| Bjartell, A | 1 |
| Ceder, Y | 1 |
| Lamoureux, F | 1 |
| Zoubeidi, A | 1 |
| Ringer, L | 2 |
| Sirajuddin, P | 2 |
| Tricoli, L | 1 |
| Waye, S | 1 |
| Choudhry, MU | 1 |
| Parasido, E | 1 |
| Sivakumar, A | 1 |
| Heckler, M | 1 |
| Naeem, A | 1 |
| Abdelgawad, I | 1 |
| Liu, X | 1 |
| Feldman, AS | 1 |
| Lee, RJ | 1 |
| Wu, CL | 1 |
| Yenugonda, V | 1 |
| Kallakury, B | 1 |
| Dritschilo, A | 1 |
| Lynch, J | 1 |
| Schlegel, R | 1 |
| Rodriguez, O | 2 |
| Pestell, RG | 1 |
| Avantaggiati, ML | 2 |
| Albanese, C | 2 |
| Pickard, RD | 1 |
| Spencer, BH | 1 |
| McFarland, AJ | 1 |
| Bernaitis, N | 1 |
| Davey, AK | 1 |
| Perkins, AV | 1 |
| Chess-Williams, R | 1 |
| McDermott, CM | 1 |
| Forbes, A | 1 |
| Christie, D | 1 |
| Anoopkumar-Dukie, S | 1 |
| Kokabee, L | 1 |
| Wang, X | 1 |
| Sevinsky, CJ | 1 |
| Wang, WL | 1 |
| Cheu, L | 1 |
| Chittur, SV | 1 |
| Karimipoor, M | 1 |
| Tenniswood, M | 1 |
| Conklin, DS | 1 |
| Bistulfi, G | 1 |
| Gillard, B | 1 |
| Morrison, C | 1 |
| Mohler, J | 1 |
| Beharry, AA | 1 |
| Lacoste, S | 1 |
| O'Connor, TR | 1 |
| Kool, ET | 1 |
| Hu, H | 1 |
| Chai, Y | 1 |
| Wang, L | 1 |
| Zhang, J | 1 |
| Lee, HJ | 1 |
| Kim, SH | 1 |
| Lü, J | 1 |
| Paprotka, T | 1 |
| Venkatachari, NJ | 1 |
| Chaipan, C | 1 |
| Burdick, R | 1 |
| Delviks-Frankenberry, KA | 1 |
| Hu, WS | 1 |
| Pathak, VK | 1 |
| Yenugonda, VM | 1 |
| Ghosh, A | 1 |
| Divito, K | 1 |
| Trabosh, V | 1 |
| Patel, Y | 1 |
| Brophy, A | 1 |
| Grindrod, S | 1 |
| Lisanti, MP | 1 |
| Rosenthal, D | 1 |
| Brown, ML | 1 |
| Zhang, XQ | 1 |
| Huang, XF | 1 |
| Hu, XB | 1 |
| Zhan, YH | 1 |
| An, QX | 1 |
| Yang, SM | 1 |
| Xia, AJ | 1 |
| Yi, J | 1 |
| Chen, R | 1 |
| Mu, SJ | 1 |
| Wu, DC | 1 |
| Tanowitz, HB | 1 |
| Machado, FS | 1 |
| Scaffidi, JP | 1 |
| Gregas, MK | 1 |
| Lauly, B | 1 |
| Zhang, Y | 1 |
| Vo-Dinh, T | 1 |
| Tzenaki, N | 1 |
| Andreou, M | 1 |
| Stratigi, K | 1 |
| Vergetaki, A | 1 |
| Makrigiannakis, A | 1 |
| Vanhaesebroeck, B | 1 |
| Papakonstanti, EA | 1 |
| Schmukler, E | 1 |
| Shai, B | 1 |
| Ehrlich, M | 1 |
| Pinkas-Kramarski, R | 2 |
| Giampietri, C | 1 |
| Petrungaro, S | 1 |
| Padula, F | 1 |
| D'Alessio, A | 1 |
| Marini, ES | 1 |
| Facchiano, A | 1 |
| Filippini, A | 1 |
| Ziparo, E | 1 |
| Tal-Or, P | 1 |
| Di-Segni, A | 1 |
| Lupowitz, Z | 1 |
| Trzeciak, AR | 1 |
| Nyaga, SG | 1 |
| Jaruga, P | 1 |
| Lohani, A | 1 |
| Dizdaroglu, M | 1 |
| Evans, MK | 1 |
| Wang, XY | 1 |
| Martiniello-Wilks, R | 2 |
| Shaw, JM | 1 |
| Ho, T | 1 |
| Coulston, N | 1 |
| Cooke-Yarborough, C | 1 |
| Molloy, PL | 1 |
| Cameron, F | 1 |
| Moghaddam, M | 1 |
| Lockett, TJ | 1 |
| Webster, LK | 1 |
| Smith, IK | 1 |
| Both, GW | 2 |
| Russell, PJ | 2 |
| Powell, IJ | 1 |
| Land, SJ | 1 |
| Dey, J | 1 |
| Heilbrun, LK | 1 |
| Hughes, MR | 1 |
| Sakr, W | 1 |
| Everson, RB | 1 |
| Pérez-Roldán, F | 1 |
| González-Carro, P | 1 |
| Villafáñez-García, MC | 1 |
| Seppälä, EH | 1 |
| Autio, V | 1 |
| Duggal, P | 1 |
| Ikonen, T | 1 |
| Stenman, UH | 1 |
| Auvinen, A | 1 |
| Bailey-Wilson, JE | 1 |
| Tammela, TL | 1 |
| Schleutker, J | 1 |
| Dunzendorfer, U | 1 |
| Releyea, N | 1 |
| Whitmore, WF | 1 |
| Fogh, J | 1 |
| Balis, ME | 1 |
| Marshall, ME | 1 |
| Blumenstein, B | 1 |
| Crawford, ED | 1 |
| Thompson, IM | 1 |
| Craig, JB | 2 |
| Eisenberger, M | 1 |
| Ahmann, F | 1 |
| Robbins, SE | 1 |
| Shu, WP | 1 |
| Kirschenbaum, A | 1 |
| Levine, AC | 1 |
| Miniati, DN | 1 |
| Liu, BC | 1 |
| Malins, DC | 1 |
| Johnson, PM | 1 |
| Wheeler, TM | 1 |
| Barker, EA | 1 |
| Polissar, NL | 1 |
| Vinson, MA | 1 |
| Erkkilä, K | 1 |
| Aito, H | 1 |
| Aalto, K | 1 |
| Pentikäinen, V | 1 |
| Dunkel, L | 1 |
| Voeks, D | 1 |
| Madden, V | 1 |
| Smith, K | 1 |
| Bennetts, E | 1 |
| Gilbert, SM | 1 |
| Benson, MC | 1 |
| McKiernan, JM | 1 |
| Gelmann, EP | 1 |
| Saez, R | 1 |
| Kuhn, JG | 1 |
| Weiss, GR | 1 |
| Koeller, J | 1 |
| Phillips, J | 1 |
| Havlin, K | 1 |
| Harman, G | 1 |
| Hardy, J | 1 |
| Melink, TJ | 1 |
2 reviews available for adenine and Cancer of Prostate
| Article | Year |
|---|---|
Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population.
Topics: Adenine; Black People; Cytosine; Guanosine; Humans; Linkage Disequilibrium; Male; Prostatic Neoplasm | 2002 |
Molecular biology of the androgen receptor.
Topics: Adenine; Animals; Cytosine; Guanine; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Risk; T | 2002 |
2 trials available for adenine and Cancer of Prostate
| Article | Year |
|---|---|
Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedul | 1994 |
Phase I clinical investigation of amonafide.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pr | 1989 |
32 other studies available for adenine and Cancer of Prostate
| Article | Year |
|---|---|
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenine; Androgens; Cytosine; Guanine; Humans; Male; Membrane | 2022 |
Deacetylation of LAMP1 drives lipophagy-dependent generation of free fatty acids by Abrus agglutinin to promote senescence in prostate cancer.
Topics: Adenine; Apoptosis; Autophagy; Benzamides; Carbamates; Cell Line, Tumor; Cell Proliferation; Cellula | 2020 |
Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy.
Topics: Acetyltransferases; Adenine; Animals; Apoptosis; Cell Line, Tumor; Drug Therapy, Combination; Humans | 2020 |
Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Topics: Adenine; Autophagy; Chloroquine; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Male; | 2020 |
Autophagy Induction by α-Santalol in Human Prostate Cancer Cells.
Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Humans; Male; Microtubule-Associated Proteins; Phos | 2021 |
Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery.
Topics: Adenine; Biomarkers, Tumor; Cohort Studies; Humans; Inosine; Male; MicroRNAs; Prostatic Hyperplasia; | 2021 |
Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Topics: Adenine; Autophagy; Cell Line, Tumor; Chloroquine; Clinical Trials, Phase I as Topic; Humans; Macrol | 2013 |
The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.
Topics: Adenine; Apoptosis; Autophagy; Blotting, Western; Cell Proliferation; Dansyl Compounds; Flow Cytomet | 2014 |
Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Culture Techniques; Cell Line, Tumor; Cel | 2015 |
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis Regulatory Proteins; | 2015 |
The essential role of methylthioadenosine phosphorylase in prostate cancer.
Topics: Adenine; Adenocarcinoma; Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Humans; Male; Me | 2016 |
Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker.
Topics: Adenine; AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase; Animals; Antineoplastic Agents, | 2016 |
Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.
Topics: Adenine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Caspases; Cell Cycl | 2009 |
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Cell Line, Tumor; Cytidine Deaminase; Gammaretrovirus; Humans; L | 2010 |
VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor | 2010 |
Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Drug Screening Assays, Antit | 2010 |
New therapies for prostate cancer?
Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cycl | 2010 |
Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation.
Topics: Adenine; Apoptosis; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; Ficusin; Humans; Male; | 2011 |
High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Topics: Adenine; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinosi | 2012 |
Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition.
Topics: Acetylcysteine; Adenine; Anthracenes; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Death | 2012 |
Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis.
Topics: Adenine; Apoptosis; Autophagy; Blotting, Western; CASP8 and FADD-Like Apoptosis Regulating Protein; | 2012 |
Neuregulin promotes autophagic cell death of prostate cancer cells.
Topics: Adenine; Amino Acid Chloromethyl Ketones; Autophagy; Cell Death; Cell Division; Chromones; Cysteine | 2003 |
Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145.
Topics: Adenine; Antioxidants; Blotting, Western; Catalase; Cell Division; Cell Line, Tumor; Cell Nucleus; C | 2004 |
Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Replic | 2004 |
The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy.
Topics: Adenine; Age Factors; Aged; Black People; Cytosine; Disease Progression; Exons; Genotype; Guanine; H | 2005 |
Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection.
Topics: Acute Disease; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hepa | 2005 |
KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.
Topics: Adenine; Finland; Genetic Variation; Genotype; Germ-Line Mutation; Guanine; Humans; Kruppel-Like Fac | 2007 |
Some effects of inhibitors of polyamine synthesis on experimental prostatic cancer.
Topics: Adenine; Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Carboxy-Lyases; Eflornithine; Gu | 1984 |
Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells.
Topics: Adenine; Androgens; Animals; Base Sequence; Binding Sites; Bone and Bones; Cell Division; Dihydrotes | 1996 |
Age-related radical-induced DNA damage is linked to prostate cancer.
Topics: Adenine; Age Factors; Cell Transformation, Neoplastic; DNA; DNA Damage; DNA, Neoplasm; Gas Chromatog | 2001 |
Lactate inhibits germ cell apoptosis in the human testis.
Topics: Adenine; Aged; Aged, 80 and over; Apoptosis; Culture Techniques; fas Receptor; Humans; In Situ Nick- | 2002 |
Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
Topics: Adenine; Animals; Avian Sarcoma Viruses; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; | 2002 |